Equities Analysts Set Expectations for Nkarta Q3 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Nkarta in a report released on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.46) for the quarter, down from their previous forecast of ($0.41). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Nkarta’s Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.53) EPS and FY2030 earnings at ($1.23) EPS.

NKTX has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Wednesday, June 24th. Evercore set a $9.00 target price on Nkarta in a research report on Monday, May 18th. TD Cowen began coverage on shares of Nkarta in a report on Tuesday, June 23rd. They set a “buy” rating on the stock. Wall Street Zen raised shares of Nkarta from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Nkarta in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Nkarta Stock Up 2.6%

NKTX opened at $2.39 on Thursday. The business’s fifty day simple moving average is $2.65 and its 200 day simple moving average is $2.58. Nkarta has a 52 week low of $1.70 and a 52 week high of $3.72. The stock has a market cap of $170.98 million, a PE ratio of -1.52 and a beta of 0.93.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.18).

Institutional Trading of Nkarta

Several hedge funds have recently bought and sold shares of NKTX. BlackRock Inc. purchased a new stake in shares of Nkarta during the 2nd quarter valued at about $17,830,000. GSK plc purchased a new stake in Nkarta during the fourth quarter valued at approximately $5,829,000. Monaco Asset Management SAM lifted its stake in shares of Nkarta by 29.2% in the 4th quarter. Monaco Asset Management SAM now owns 2,546,932 shares of the company’s stock valued at $4,712,000 after purchasing an additional 576,022 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Nkarta by 1.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,732,372 shares of the company’s stock worth $3,655,000 after purchasing an additional 30,350 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Nkarta by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock worth $2,006,000 after purchasing an additional 10,065 shares during the period. Hedge funds and other institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.